CN114206921B - 与疟原虫环子孢子蛋白结合的抗体及其用途 - Google Patents

与疟原虫环子孢子蛋白结合的抗体及其用途 Download PDF

Info

Publication number
CN114206921B
CN114206921B CN202080034143.8A CN202080034143A CN114206921B CN 114206921 B CN114206921 B CN 114206921B CN 202080034143 A CN202080034143 A CN 202080034143A CN 114206921 B CN114206921 B CN 114206921B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080034143.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114206921A (zh
Inventor
达维德·科尔蒂
卢卡·皮科利
卡特娅·芬克
伊丽莎白·卡梅罗尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Vir Biotechnology Inc
Original Assignee
Humabs Biomed SA
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA, Vir Biotechnology Inc filed Critical Humabs Biomed SA
Publication of CN114206921A publication Critical patent/CN114206921A/zh
Application granted granted Critical
Publication of CN114206921B publication Critical patent/CN114206921B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080034143.8A 2019-04-30 2020-04-30 与疟原虫环子孢子蛋白结合的抗体及其用途 Active CN114206921B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/061135 2019-04-30
PCT/EP2019/061135 WO2020221451A1 (en) 2019-04-30 2019-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof
PCT/EP2020/062167 WO2020221910A1 (en) 2019-04-30 2020-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Publications (2)

Publication Number Publication Date
CN114206921A CN114206921A (zh) 2022-03-18
CN114206921B true CN114206921B (zh) 2024-05-14

Family

ID=66429360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034143.8A Active CN114206921B (zh) 2019-04-30 2020-04-30 与疟原虫环子孢子蛋白结合的抗体及其用途

Country Status (13)

Country Link
US (1) US20230084102A1 (https=)
EP (1) EP3962513A1 (https=)
JP (1) JP2022531552A (https=)
KR (1) KR20220004055A (https=)
CN (1) CN114206921B (https=)
AU (1) AU2020266283A1 (https=)
BR (1) BR112021016341A2 (https=)
CA (1) CA3130805A1 (https=)
EA (1) EA202192930A1 (https=)
IL (1) IL285282A (https=)
MX (1) MX2021013252A (https=)
SG (1) SG11202108585QA (https=)
WO (2) WO2020221451A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
WO2022251585A2 (en) * 2021-05-28 2022-12-01 David Weiner Dna antibody constructs for use against plasmodium parasites
CN117467005A (zh) * 2023-11-15 2024-01-30 深圳重链生物科技有限公司 抗疟原虫单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056653A (zh) * 2004-09-16 2007-10-17 葛兰素史密丝克莱恩生物有限公司 包含疟原虫抗原的疫苗
CN103025349A (zh) * 2009-08-18 2013-04-03 洛克菲勒大学 采用免疫原性的疟原虫环子孢子蛋白表位的重组腺病毒的修饰
CN103611151A (zh) * 2013-12-06 2014-03-05 广东药学院 疟原虫环子孢子蛋白多肽CSP I-plus 在制备抗疟疾药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
WO2018193063A2 (en) * 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056653A (zh) * 2004-09-16 2007-10-17 葛兰素史密丝克莱恩生物有限公司 包含疟原虫抗原的疫苗
CN103025349A (zh) * 2009-08-18 2013-04-03 洛克菲勒大学 采用免疫原性的疟原虫环子孢子蛋白表位的重组腺病毒的修饰
CN103611151A (zh) * 2013-12-06 2014-03-05 广东药学院 疟原虫环子孢子蛋白多肽CSP I-plus 在制备抗疟疾药物中的应用

Also Published As

Publication number Publication date
SG11202108585QA (en) 2021-11-29
CA3130805A1 (en) 2020-11-05
US20230084102A1 (en) 2023-03-16
WO2020221451A1 (en) 2020-11-05
AU2020266283A1 (en) 2021-09-02
CN114206921A (zh) 2022-03-18
MX2021013252A (es) 2021-11-17
IL285282A (en) 2021-09-30
EP3962513A1 (en) 2022-03-09
KR20220004055A (ko) 2022-01-11
WO2020221910A1 (en) 2020-11-05
EA202192930A1 (ru) 2022-02-24
BR112021016341A2 (pt) 2021-10-26
JP2022531552A (ja) 2022-07-07

Similar Documents

Publication Publication Date Title
JP7514363B2 (ja) Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
TWI417299B (zh) 包括抗體、抗體衍生物及抗體片段之專一性地結合至ｃｄ１５４之結合蛋白及其用途
US9481731B2 (en) Toll-like receptor 3 antagonists
KR102014066B1 (ko) 항 α-syn 항체 및 그 용도
US20140286957A1 (en) ANTIBODIES TO CD1d
JP2019524052A (ja) ＦｃγＲＩＩＡに特異的な結合分子及びその使用
CN114206921B (zh) 与疟原虫环子孢子蛋白结合的抗体及其用途
EP3757127A1 (en) Deimmunized antibodies binding to alpha-4 integrin and uses thereof
US20230406925A1 (en) Siglec-8 binding proteins and uses thereof
JP2024535124A (ja) 破傷風毒素に結合する抗体およびその使用
EP2755685A1 (en) Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
EP4215544A1 (en) Monoclonal antibody for coronavirus spike protein, and use thereof
HK40070165A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
US20240034772A1 (en) Antibodies binding to f-protein of metapneumovirus and uses thereof
WO2025045250A1 (en) Anti-human factor d antibody constructs and uses thereof
OA20886A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof.
CN116848133A (zh) 结合偏肺病毒f蛋白的抗体及其用途
WO2025171256A1 (en) Compositions and methods for treating malaria
IL322413A (en) Variants of anti-CSP antibody
CN119604534A (zh) 1型大麻素受体结合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40070165

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant